Clinical trials: Keratosis
Actinic Keratosis
A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study
This study is designed to follow up patients, who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to assess both recurrence of Actinic Keratosis (AK)…
- Trial name
- NCT00952783
- Testing
- Lesion count
- Where
- 11 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Peplin
Actinic Keratosis
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic…
- Trial name
- NCT00953732
- Testing
- Lesion count
- Where
- 42 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Peplin
Actinic Keratosis
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions…
- Trial name
- NCT00989313
- Testing
- Lesion count
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Peplin
Actinic Keratosis
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.
- Trial name
- NCT00107965
- Testing
- PEP005
- Where
- 6 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Keratosis
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
The purpose of this study is : To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses.
- Trial name
- NCT00239135
- Testing
- PEP005
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Peplin
Actinic Keratoses
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
- Trial name
- NCT00742391
- Testing
- PEP005 (ingenol mebutate) Gel, Vehicle gel
- Where
- 20 sites in United States, Australia
- Volunteers
- 255 people
- Sponsor
- Peplin
Actinic Keratosis
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
- Trial name
- NCT00852137
- Testing
- PEP005 (ingenol mebutate) Gel, 0.05%, Vehicle Gel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Peplin
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00915551
- Testing
- PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 278 people
- Sponsor
- Peplin
Actinic Keratoses
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
- Trial name
- NCT00942604
- Testing
- PEP005 (ingenol mebutate) Gel, Vehicle gel
- Where
- 17 sites in United States
- Volunteers
- 203 people
- Sponsor
- Peplin
Actinic Keratoses
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
The purpose of this study is to determine the extent of systemic absorption of PEP005 when applied topically for the treatment of actinic keratoses.
- Trial name
- NCT00544258
- Testing
- PEP005
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Peplin
Actinic Keratoses
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
This is a double-blind, randomized, placebo-controlled, three treatment parallel study in which normal, healthy men and women (age 45-85) with actinic keratosis will be treated on the face once daily for two weeks with…
- Trial name
- NCT01354717
- Testing
- Brand Carac, Generic 0.5% 5-fluorouracil cream
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Spear Pharmaceuticals
Actinic Keratosis Olsen Grade I/II
Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis
In this three-armed dose-finding trial 3 AK 3012 topical formulations shall be investigated with respect to safety and efficacy in order to identify the optimal concentration in the topical formulation.
- Trial name
- NCT01757613
- Testing
- AK 3012
- Where
- 9 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Dolorgiet GmbH & Co. KG
Actinic Keratosis, Bowen's Disease
Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis
To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's Disease) reduced at least 75%.
- Trial name
- AK (NCT02085395)
- Testing
- SR-T100 ® Gel
- Where
- Taiwan
- Volunteers
- 27 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Actinic Keratosis
Bioequivalence Study of Two Imiquimod Cream 5%
The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00828568
- Testing
- Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
- Where
- 20 sites in United States
- Volunteers
- 425 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Actinic Keratosis
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera…
- Trial name
- NCT01742663
- Testing
- Diclofenac Sodium Gel 3%, Solaraze® (diclofenac sodium) Gel 3%, Vehicle Topical Gel
- Volunteers
- 435 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Actinic Keratosis
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
The objective of this study is to compare the relative efficacy and safety of the test formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod) 3.75% Topical Cream in the treatment of actinic…
- Trial name
- NCT01788007
- Testing
- Imiquimod Topical Cream 3.75%, Zyclara® (imiquimod) Topical Cream 3.75%, Vehicle Topical Cream
- Volunteers
- 443 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Precancerous Condition
T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum
RATIONALE: Patients with xeroderma pigmentosum are more likely to develop skin lesions in sun-affected areas. These skin lesions, such as actinic keratoses, can develop into skin cancer.
- Trial name
- NCT00002811
- Testing
- liposomal T4N5 lotion
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Applied Genetics
Actinic Keratosis
Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis
The purpose of this study is to assess the efficacy, safety and tolerability of Eryfotona AK-NMSC® topical application vs Sunscreen on cancerization field of actinic keratosis patients after 6 months of treatment.
- Trial name
- NCT01656226
- Testing
- Eryfotona AK-NMSC® cream, Sunscreen SPF 50+
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- ISDIN
Actinic Keratosis
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a study involving 96 patients with actinic keratosis on the head or face.
- Trial name
- NCT01611480
- Testing
- Imiquimod (topical use)
- Where
- Germany
- Sponsor
- Moberg Pharma AB
Keratosis, Actinic
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
The purpose of this study is to determine if Levulan PDT is safe and effective in the treatment of actinic keratoses on the upper arms and hands.
- Trial name
- NCT01458587
- Testing
- Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- DUSA Pharmaceuticals, Inc.